CTI BioPharma, a Seattle-based publicly traded biotech company developing therapies for blood-related cancers, is set to be acquired in a deal with Swedish biotech giant Sobi.
The acquisition, announced Wednesday, values CTI at $1.7 billion, nearly double the company’s current market capitalization at end of trading Tuesday. Shares of CTI spiked on Wednesday following the acquisition announcement.
